If you saw $999.07 on the ground, you’d pick it up, right? Jannik Sinner🔐
Couple things:
•Sinner is GUARANTEED to win
•Foazn won’t wake up at 5am to watch
I make money in my sleep; you wake up to make money #levels
$FOUR solid growth guide overall, GB weighing but will take time (we knew that). Good buyback usage so far. Main question from the slide deck is explicitly mentioning whether the expected TRA settlement cost is reflected within the ‘incremental flow through’ of the 2026 adj FCF slide. Would go a long long way in clarifying.
$LMND $ROOT The discourse that Lemonade and Root are competing against each other is so incredibly silly, I cannot comprehend it. Both have immaterial market share in personal lines right now. They are the disruptors aiming to whittle away market share from the incumbents. Bulls of each should be rooting for the success of both as it represents validation of the greater insurtech category
Beginner investors see this and assume that “hey, this guy is saying outlandish things, he must know a thing or two”. But no. It’s a cash grab, same as it ever was.
Linares is one of the most incredible marketers I’ve ever seen. No one is doing it like him (not an endorsement). I mean..what kind of message is this?
@atelicinvest It’s so important to learn the right lessons from these things. (And sometimes, that “lesson” really is that no one really knows anything)
@TravisHoium This seems very hopeful to me. 1x glp1 injectable revs since shortage ended is probably $500mm of damages and they’re continuing to sell it…..god forbid if they have to pay based on Novo’s retail value
But wishing you the best of luck
I would like to long $OSCR again at some point. After a washout year for the industry in ‘25 no one believes in guidance, but with every quarter it’s met the market’s confidence will grow.
Diving just a tad deeper, Oscar’s specialized plans (after Hims I won’t use the p-word) position it for share gains and an early leader in ICHRA as that gradually rolls out over the next 1-2 decades. Seems pretty darn attractive here and stock is actually lower than my buys last summer.
Oscar Health with a Giga 2026 outlook.
Revenue guidance of $18.9b (+61%)
$350 million earnings from operations vs 3650 market cap.
SGA expense ratio scaling to 16% vs 17.5% in 2025 and 19.1% in 2024.
$OSCR
$TOST $FOUR The mix of software, hardware & payments isn’t going anywhere. (No surprise to anyone that’s been paying attention.)
Toast CEO when asked about AI impact: “[We’re] the most important piece of technology restauranteurs use around their business [where] all the work gets done…and it’s really broad.” ⬇️
I’ve been a $LMND skeptic for a long time and the jury is still out on bottom line, but my goodness that auto GLR (gross loss ratio) is an incredibly positive rate of change. Seems like a really good report
Fantastic Q4 for $LMND
Record low GLR, record low Car GLR TTM (see note), Europe numbers looking great, home/renters unbelievably low.
Share price fully deserves to run after this (NFA, IMO)